- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01710761
Effects of Neo40(TM) With Caffeine on Cycling Time Trial Performance
January 22, 2013 updated by: University of Texas at Austin
Acute supplementation of Neo40(TM), a nitrate lozenge, will improve cycling performance
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
16
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78712
- The University of Texas at Austin
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 49 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Regular commuter cyclist or spin class participant
- Male (VO2max < 50) or Female (VO2max < 45)
- Healthy
- Blood pressure below 140/90
- Non-smoker
Exclusion Criteria:
- Does not cycle 2-3 times/week
- Regular consumption of performance-enhancing substances
- Type I or Type II diabetes
- Renal, hepatic or cardiac disease
- Current infectious disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Same form factor and flavor as test lozenge but contains no active ingredients
|
|
Active Comparator: Nitrate supplement with caffeine
|
Lozenge consisting of beetroot and 75 mg caffeine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Improved Time Trial Performance
Time Frame: After 20 min steady-state cycling
|
Participants will cycle 20 min at increasing intensity: 8 min at 55% VO2max, 6 min at 65% VO2max, 6 min at 75% VO2max.
The 20 km time trial consists of rolling hills.
|
After 20 min steady-state cycling
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Improved work efficiency
Time Frame: During 20 min steady-state cycling
|
Expired gases will be collected and compared to expected VO2.
Blood will be collected prior to treatment, prior to exercise and during each cycling intensity to analyze lactate accumulation.
|
During 20 min steady-state cycling
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Lynne Kammer-Kerwick, MSE, MA, The University of Texas at Austin
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2012
Primary Completion (Anticipated)
February 1, 2013
Study Completion (Anticipated)
May 1, 2013
Study Registration Dates
First Submitted
October 17, 2012
First Submitted That Met QC Criteria
October 17, 2012
First Posted (Estimate)
October 19, 2012
Study Record Updates
Last Update Posted (Estimate)
January 23, 2013
Last Update Submitted That Met QC Criteria
January 22, 2013
Last Verified
January 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012-05-0033
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.